<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02123004</url>
  </required_header>
  <id_info>
    <org_study_id>ISSBRIL0249</org_study_id>
    <secondary_id>Brilinta-0249</secondary_id>
    <nct_id>NCT02123004</nct_id>
  </id_info>
  <brief_title>Comparison of Ticagrelor And Clopidogrel on Inflammatory Biomarkers And Vascular Endothelial Function</brief_title>
  <acronym>TIGERCAVE</acronym>
  <official_title>Comparison of The Influence of Ticagrelor And Clopidogrel on Inflammatory Biomarkers And Vascular Endothelial Function For Patients With ST-Segment Elevation Myocardial Infarction Receiving Emergency Percutaneous Coronary Intervention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jinan Central Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jinan Central Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. Ticagrelor inhibits inflammation and improves vascular endothelial cell function to a&#xD;
           greater extent than clopidogrel in ST-segment elevation myocardial infarction(STEMI)&#xD;
           patients receiving percutaneous coronary intervention.&#xD;
&#xD;
        2. Ticagrelor can reduce the serum levels of inflammatory biomarkers both in coronary and&#xD;
           in peripheral venous in patients with ST-segment elevation myocardial infarction(STEMI).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Platelet participates in the process of forming and extending atherosclerotic plaques, and it&#xD;
      is also a source of inflammatory mediators. This study is a randomized, open-label study,&#xD;
      designed to test the hypothesis that ticagrelor inhibits inflammation and improves vascular&#xD;
      endothelial cell function to a greater extent than clopidogrel in ST-segment elevation&#xD;
      myocardial infarction(STEMI) patients receiving percutaneous coronary intervention. Patients&#xD;
      who are scheduled to undergo emergency Percutaneous Coronary Intervention(PCI) will be&#xD;
      randomly assigned to receive ticagrelor 180mg for treatment group or clopidogrel 600mg for&#xD;
      control group ,then after Percutaneous Coronary Intervention(PCI) treatment group treated&#xD;
      with ticagrelor 90mg twice daily while the control group received clopidogrel 75mg once a day&#xD;
      . All patients should receive Acetylsalicylic Acid(ASA) 300 mg as a loading dose before&#xD;
      Percutaneous Coronary Intervention(PCI) then 100 mg daily unless intolerant. Glycoprotein&#xD;
      Ⅱb/Ⅲa receptor antagonists and low-molecular-weight heparin and other additional medication&#xD;
      will be directed by the treating cardiologist. All interventions will be performed via the&#xD;
      radial approach with the standard technique within 12h after they are involved, and&#xD;
      drug-eluting stents will be placed according to stenosis of coronary artery.&#xD;
&#xD;
      The vascular endothelial function will be tested by Circulating Endothelial Cells (CECs) and&#xD;
      levels of inflammation will be tested by CD40 ligand (CD40L), C-reactive protein (CRP), and&#xD;
      P-selectin to identify that ticagrelor inhibits inflammation and improves vascular&#xD;
      endothelial cell function to a greater extent than clopidogrel.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">August 2016</completion_date>
  <primary_completion_date type="Anticipated">May 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CD40 Ligand(CD40l)/C-reactive protein(CRP)/P-selectin and Circulating Endothelial Cells(CECs)</measure>
    <time_frame>0 -4 weeks</time_frame>
    <description>The peripheral venous serum level of CD40 Ligand(CD40l)/C-reactive protein(CRP)/P-selectin and Circulating Endothelial Cells(CECs), 0 hour after dosing and 4 weeks after Percutaneous Coronary Intervention(PCI).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CD40 Ligand(CD40l)/C-reactive protein(CRP)/P-selectin and Circulating Endothelial Cells(CECs)</measure>
    <time_frame>24hour after dosing</time_frame>
    <description>The peripheral venous serum level of CD40 Ligand(CD40l)/C-reactive protein(CRP)/P-selectin and Circulating Endothelial Cells(CECs), 24hour after dosing and 1 weeks after Percutaneous Coronary Intervention(PCI);</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD40 Ligand(CD40l)/C-reactive protein(CRP)/P-selectin and Circulating Endothelial Cells(CECs)</measure>
    <time_frame>1 weeks after Percutaneous Coronary Intervention</time_frame>
    <description>The peripheral venous serum level of CD40 Ligand(CD40l)/C-reactive protein(CRP)/P-selectin and Circulating Endothelial Cells(CECs),24hour after dosing and 1 weeks after Percutaneous Coronary Intervention(PCI);</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD40 Ligand(CD40l)/C-reactive protein(CRP)/P-selectin and Circulating Endothelial Cells(CECs)</measure>
    <time_frame>1 hour after dosing</time_frame>
    <description>the coronary serum level of CD40 Ligand(CD40l)/C-reactive protein(CRP)/P-selectin and Circulating Endothelial Cells(CECs),1 hour after dosing;</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse Event</measure>
    <time_frame>during 4 weeks follow up</time_frame>
    <description>The safety objective of this study in patients will be evaluated by the occurrence of any Adverse Event(AEs) during 4 weeks follow up.Suspected bleeding/reinfarction /rehospitalization /revascularization by Percutaneous Coronary Intervention(PCI) or coronary artery bypass graft (CABG) / sudden death/ stoke /allergic or allergic-like reactions and other adverse events and serious adverse events.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">350</enrollment>
  <condition>ST-Segment Elevation Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Ticagrelor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Investigational product/Dosage form and strength/Manufacturer:&#xD;
ticagrelor/tablet /90mg/AstraZeneca 180mg loading dose for one day ,then 90mg per day for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clopidogrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Investigational product/Dosage form and strength/Manufacturer:&#xD;
clopidogrel/tablet /75mg/Sanofi 300mg loading dose for one day ,then 75mg per day for 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor</intervention_name>
    <description>180mg loading dose for one day ,and then 90mg per day for 4 weeks</description>
    <arm_group_label>Ticagrelor</arm_group_label>
    <other_name>Brilinta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>300mg loading dose for one day ,and then 75mg per day for 4 weeks</description>
    <arm_group_label>Clopidogrel</arm_group_label>
    <other_name>plavix</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or non-pregnant female.&#xD;
&#xD;
          2. Age ≥ 18 years old and &lt;80 years old.&#xD;
&#xD;
          3. Consecutive patients who should be hospitalized with documented evidence of ST-Segment&#xD;
             Elevation Myocardial Infarction receiving Percutaneous Coronary Intervention.&#xD;
&#xD;
          4. All patients havepersistent≥0.2 Millivolt ST segment elevation in two or more&#xD;
             contiguous precordial leads or ≥0.1 Millivolt ST elevation in two or more contiguous&#xD;
             limb leads, with one of the following: persistent chest pain or elevatory of&#xD;
             biomarkers of myocardial necrosis.&#xD;
&#xD;
          5. Time from chest pain onset to receiving Percutaneous Coronary Intervention &lt;12 hours.&#xD;
&#xD;
          6. Persistent chest pain &lt;12 hours.&#xD;
&#xD;
          7. Provision of informed consent prior to any study specific procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Involved in other trials.&#xD;
&#xD;
          2. In recent one year have P 2 Y 12 receptor antagonist drug treatment history or&#xD;
             long-term use of immunosuppressive agents.&#xD;
&#xD;
          3. Recurrent myocardial infarction or previous history of Coronary Artery Bypass&#xD;
             Graft(CABG) surgery or rescue Percutaneous Coronary Intervention.&#xD;
&#xD;
          4. Active bleeding or bleeding history.&#xD;
&#xD;
          5. With obvious infection and body temperature (axillary temperature) higher than 38.0 ℃.&#xD;
&#xD;
          6. Autoimmune diseases.&#xD;
&#xD;
          7. Malignancies.&#xD;
&#xD;
          8. In recent 6 months have received major surgery.&#xD;
&#xD;
          9. Left ventricular ejection fraction is less than 30%.&#xD;
&#xD;
         10. Life expectancy less than one year.&#xD;
&#xD;
         11. With moderate and severe liver function deterioration.&#xD;
&#xD;
         12. End-stage renal failure.&#xD;
&#xD;
         13. Other conditions that may put the patient at risk or influence study results in the&#xD;
             investigators' opinion：eg, increased risk of bradycardiac events; known clinically&#xD;
             important thrombocytopenia; known clinically important anemia; severe hemodynamic&#xD;
             instability.&#xD;
&#xD;
         14. Other contraindications to investigate products.&#xD;
&#xD;
         15. Any condition that increases the risk for noncompliance or being lost to follow-up.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Su Guohai, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jinan Central Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Su Guohai, Doctor</last_name>
    <phone>+86(0)13370582008</phone>
    <email>guohaisu@medmail.com.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Jinan Central Hospital</name>
      <address>
        <city>Jinan Shi</city>
        <state>Shandong</state>
        <zip>250013</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Su Guohai, Doctor</last_name>
      <phone>+86(0)13370582008</phone>
      <email>guohaisu@medmail.com.cn</email>
    </contact>
    <contact_backup>
      <last_name>Li Zhenhua, Doctor</last_name>
      <phone>+86(0)13969081430</phone>
      <email>lizhenhua675@126.com</email>
    </contact_backup>
    <investigator>
      <last_name>Su Guohai, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Li Zhenhua, Doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <study_first_submitted>April 20, 2014</study_first_submitted>
  <study_first_submitted_qc>April 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2014</study_first_posted>
  <last_update_submitted>February 24, 2015</last_update_submitted>
  <last_update_submitted_qc>February 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 25, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Jinan Central Hospital</investigator_affiliation>
    <investigator_full_name>Su Guohai</investigator_full_name>
    <investigator_title>Chief Physician</investigator_title>
  </responsible_party>
  <keyword>ST-Segment Elevation Myocardial Infarction</keyword>
  <keyword>Percutaneous Coronary Intervention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

